Advanced Oncotherapy - Issue of Equity

Advanced Oncotherapy

01/12/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221201:nRSA1729Ia&default-theme=true

RNS Number : 1729I  Advanced Oncotherapy PLC  01 December 2022

1 December 2022

 

ADVANCED ONCOTHERAPY PLC

 

("Advanced Oncotherapy" or the "Company")

 

Issue of Equity

 

Advanced Oncotherapy (AIM:AVO), the developer of LIGHT, the next-generation
proton therapy system for cancer treatment, announces that the Company has
agreed to issue a total of 250,000 new ordinary shares of 25 pence in the
Company ("New Ordinary Shares") as non-cash consideration at an issue price of
price 25 pence per share (the "Issue Price") in lieu of fees due to a
financial adviser. The financial adviser has opted for his remuneration, which
relates to work performed for the quarterly period ended 29 November 2022, to
be settled through the issue of New Ordinary Shares.

 

The Issue Price represents a premium of 47.1 per cent to the closing middle
market price of an ordinary share on 30 November 2022.

 

Once issued, the New Ordinary Shares will rank pari passu in all respects with
the existing Ordinary Shares of the Company.

 

 Application has been made for the 250,000 New Ordinary Shares to be admitted
to trading on AIM ("Admission") and it is expected that Admission will occur
on or about 2 December 2022.

 

Total voting rights

 

Following Admission, the Company's enlarged issued share capital will comprise
531,481,209 ordinary shares of 25 pence each, with one voting right per share
("Ordinary Shares"). The Company does not hold any ordinary shares in treasury
and therefore the total number of Ordinary Shares with voting rights in the
Company is 531,481,209.

 

The aforementioned figure may be used by shareholders as the denominator for
the calculations by which they will determine if they are required to notify
their interest in, or a change to their interest in, the share capital of the
Company under the FCA's Disclosure Guidance and Transparency Rules.

 

- ENDS -

 

 

 Advanced Oncotherapy plc                           www.avoplc.com (http://www.avoplc.com)
 Dr Michael Sinclair, Executive Chairman            Tel: +44 (0) 20 3617 8728
 Nicolas Serandour, CEO

 Allenby Capital Limited (Nomad and Joint Broker)
 Nick Athanas / Piers Shimwell (Corporate Finance)  Tel: +44 (0) 20 3328 5656

 Amrit Nahal / Matt Butlin (Sales & Broking)

 SI Capital Ltd (Joint Broker)
 Nick Emerson                                       Tel: +44 (0) 1483 413 500
 Jon Levinson                                       Tel: +44 (0) 20 3871 4066

 FTI Consulting (Financial PR & IR)                 advancedoncotherapy@fticonsulting.com
                                                    (mailto:advancedoncotherapy@fticonsulting.com)
 Simon Conway / Rob Winder                          Tel: +44 (0) 20 3727 1000

 

Notes for Editors

 

About Advanced Oncotherapy Plc www.avoplc.com (http://www.avoplc.com/)

 

Advanced Oncotherapy, a UK headquartered company with offices in London,
Geneva, The Netherlands and in the USA, is a provider of particle therapy with
protons that harnesses the best in modern technology. Advanced Oncotherapy's
team "ADAM," based in Geneva, focuses on the development of a proprietary
proton accelerator called, Linac Image Guided Hadron Technology (LIGHT).
LIGHT's compact configuration delivers proton beams in a way that facilitates
greater precision and electronic control.

 

Advanced Oncotherapy will offer healthcare providers affordable systems that
will enable them to treat cancer with innovative technology as well as
expected lower treatment-related side effects.

 

Advanced Oncotherapy continually monitors the market for any emerging
improvements in delivering proton therapy and actively seeks working
relationships with providers of these innovative technologies. Through these
relationships, the Company will remain the prime provider of an innovative and
cost-effective system for particle therapy with protons.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEBBLLXLFLEFBD